首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2346722篇
  免费   175299篇
  国内免费   3322篇
耳鼻咽喉   32079篇
儿科学   75895篇
妇产科学   62721篇
基础医学   348496篇
口腔科学   63691篇
临床医学   211285篇
内科学   456993篇
皮肤病学   51867篇
神经病学   185387篇
特种医学   88095篇
外国民族医学   489篇
外科学   354176篇
综合类   47490篇
现状与发展   12篇
一般理论   849篇
预防医学   182553篇
眼科学   54279篇
药学   175180篇
  9篇
中国医学   4575篇
肿瘤学   129222篇
  2021年   19026篇
  2019年   19588篇
  2018年   27128篇
  2017年   20416篇
  2016年   22809篇
  2015年   25716篇
  2014年   36201篇
  2013年   54081篇
  2012年   74859篇
  2011年   79580篇
  2010年   47148篇
  2009年   44656篇
  2008年   74725篇
  2007年   79619篇
  2006年   80450篇
  2005年   77907篇
  2004年   74477篇
  2003年   71793篇
  2002年   69462篇
  2001年   108808篇
  2000年   111515篇
  1999年   93551篇
  1998年   27016篇
  1997年   23676篇
  1996年   24078篇
  1995年   22735篇
  1994年   20906篇
  1993年   19726篇
  1992年   72055篇
  1991年   70107篇
  1990年   68427篇
  1989年   65702篇
  1988年   60332篇
  1987年   59167篇
  1986年   55241篇
  1985年   53040篇
  1984年   39337篇
  1983年   33417篇
  1982年   19869篇
  1979年   35891篇
  1978年   25663篇
  1977年   21237篇
  1976年   20346篇
  1975年   21831篇
  1974年   26174篇
  1973年   24825篇
  1972年   23214篇
  1971年   22047篇
  1970年   20259篇
  1969年   19333篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy  相似文献   
12.
13.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
14.
15.
16.
BackgroundTotal hip and knee arthroplasties are increasingly performed operations, and routine follow-up places huge demands on orthopedic services. This study investigates the effectiveness, patients’ satisfaction, and cost reduction of Virtual Joint Replacement Clinic (VJRC) follow-up of total hip arthroplasty and total knee arthroplasty patients in a university hospital. VJRC is especially valuable when in-person appointments are not advised or feasible such as during the COVID-19 pandemic.MethodsA total of 1749 patients who were invited for VJRC follow-up for knee or hip arthroplasty from January 2017 to December 2018 were included in this retrospective study. Patients were referred to VJRC after their 6-week postoperative review. Routine VJRC postoperative review was undertaken at 1 and 7 years and then 3-yearly thereafter. We evaluated the VJRC patient response rate, acceptability, and outcome. Patient satisfaction was measured in a subgroup of patients using a satisfaction survey. VJRC costs were calculated compared to face-to-face follow-up.ResultsThe VJRC had a 92.05% overall response rate. Only 7.22% required further in-person appointments with only 3% being reviewed by an orthopedic consultant. VJRC resulted in an estimated saving of £42,644 per year at our institution. The patients’ satisfaction survey showed that 89.29% of the patients were either satisfied or very satisfied with VJRC follow-up.ConclusionVJRC follow-up for hip and knee arthroplasty patients is an effective alternative to in-person clinic assessment which is accepted by patients, has high patient satisfaction, and can reduce the cost to both health services and patients.  相似文献   
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号